亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

布仑妥昔单抗维多汀 ABVD公司 达卡巴嗪 医学 长春碱 内科学 化疗方案 阶段(地层学) 肿瘤科 化疗 外科 淋巴瘤 胃肠病学 霍奇金淋巴瘤 长春新碱 环磷酰胺 古生物学 生物
作者
Howland E. Crosswell,Ann S. LaCasce,Nancy L. Bartlett,David J. Straus,Kerry J. Savage,Pier Luigi Zinzani,Graham P. Collins,Michelle A. Fanale,Keenan Fenton,Cassie Dong,Harry Miao,Andrew Grigg
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 7528-7528 被引量:1
标识
DOI:10.1200/jco.2021.39.15_suppl.7528
摘要

7528 Background: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in adolescents and young adults (AYAs) which is typically defined as 15 to 39 years. Given their young age at presentation, key factors in treatment selection include a high cure rate and limiting long-term toxicities. Brentuximab vedotin (Adcetris®; A) is a CD30-directed ADC approved in combination with doxorubicin, vinblastine, and dacarbazine chemotherapy (A+AVD) for adults with previously untreated stage III/IV cHL based on results from the phase 3 ECHELON-1 trial. Recent 5-year data demonstrated a significantly improved PFS per investigator (INV) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) (HR, 0.69; 95% CI, 0.54–0.9; P = 0.003) (Straus 2020). Here we describe key efficacy and safety results for AYA pts enrolled in ECHELON-1. Methods: ECHELON-1 (N = 1334) is a global, open-label, multicenter, randomized trial of pts with previously untreated stage III/IV cHL. A total of 771 AYAs (57.8%) received either A+AVD (n = 396) or ABVD (n = 375) with a PET scan after cycle 2 (PET2). An analysis of PFS (time from randomization to progression or death from any cause) per INV was conducted. Results: After a median follow-up of 60.7 months (95% CI, 60.4-61.0), there was a 36% reduction in the risk of progression or death in AYAs receiving A+AVD vs ABVD (HR 0.64; 95% CI, 0.45-0.92; P = 0.013) with a 5-year PFS of 86.3% vs 79.4%, respectively, similar to the ITT population. The PFS benefit of A+AVD vs ABVD was independent of PET2 status; PET2 positivity (Deauville 4-5) was 6% and 8%, respectively. On the A+AVD arm, 81 AYAs (20%) had at least 1 subsequent anticancer therapy vs 96 AYAs (26%) on the ABVD arm; 26 AYAs (7%) received subsequent high dose chemotherapy and autologous stem cell transplant vs 32 AYAs (9%) on the A+AVD and ABVD arms, respectively. Resolution or improvement of peripheral neuropathy (PN) were similar in both arms; 224 AYAs (88%) on the A+AVD had resolution or improvement of PN vs 133 AYAs (89%) on the ABVD arm. Ongoing PN was predominantly Gr 1 (62%) and Gr 2 (26%), with 8 AYAs (13%) on the A+AVD arm and 1 AYA (5%) on the ABVD arm reporting ongoing Gr 3 PN. Finally, 7 AYAs (1.8%) and 5 AYAs (1.4%) on the A+AVD and ABVD arms, respectively, reported a secondary malignancy. Subsequent pregnancies were reported in female pts (44 A+AVD; 26 ABVD) and partners of male pts (31 A+AVD; 30 ABVD). No stillbirths were reported. All but 1 pt in each arm was < 40. Conclusions: Consistent with the ITT population, AYAs treated with A+AVD compared to ABVD had a durable PFS benefit at this significant 5-year milestone. No impact on the rate of secondary malignancies and a numerically greater number of pregnancies were observed, outcomes of interest to AYAs. Additionally, the majority of PN events improved or resolved over time. A+AVD should be considered a treatment option for AYAs with stage III/IV cHL. Clinical trial information: NCT01712490.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TS6539完成签到,获得积分10
3秒前
bababiba完成签到,获得积分10
6秒前
9秒前
CipherSage应助archer01采纳,获得10
18秒前
量子星尘发布了新的文献求助10
34秒前
44秒前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
2分钟前
2分钟前
2分钟前
星辰大海应助科研通管家采纳,获得10
2分钟前
3分钟前
量子星尘发布了新的文献求助10
3分钟前
月儿完成签到 ,获得积分10
3分钟前
冬去春来完成签到 ,获得积分10
3分钟前
3分钟前
小江完成签到,获得积分10
3分钟前
gszy1975完成签到,获得积分10
3分钟前
3分钟前
3分钟前
Chaos完成签到 ,获得积分10
4分钟前
光合作用完成签到,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
八个猪宝贝完成签到,获得积分10
4分钟前
量子星尘发布了新的文献求助10
5分钟前
lameliu完成签到,获得积分10
5分钟前
5分钟前
香蕉觅云应助Viiigo采纳,获得10
5分钟前
5分钟前
量子星尘发布了新的文献求助10
6分钟前
6分钟前
老石完成签到 ,获得积分10
6分钟前
chichqq发布了新的文献求助30
6分钟前
6分钟前
evil发布了新的文献求助10
6分钟前
7分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3957061
求助须知:如何正确求助?哪些是违规求助? 3503084
关于积分的说明 11111255
捐赠科研通 3234121
什么是DOI,文献DOI怎么找? 1787751
邀请新用户注册赠送积分活动 870772
科研通“疑难数据库(出版商)”最低求助积分说明 802264